https://www.murtfeldt.de/fileadmin/_processed_/9/d/csm_Murtfeldt_Crosslink_Anwenderbericht_AB_CT_MammaCT__72__1be08df7c7.jpg

Breakthrough in medical technology

nu:view sets new standards in computed tomography



A real breakthrough in the world of medical technology - made in Germany. nu:view sets new standards in computed tomography for the early detection of breast cancer: with high-resolution, superimposition-free 3D images in record time - without any compression of the sensitive tissue. 


The nu:view computed tomography device from Advanced Breast-CT (AB-CT), based in Erlangen, Germany, uses state-of-the-art technology and components to produce unparalleled image quality that is revolutionising the early detection of breast cancer. In collaboration with Crosslink Murtfeldt Composites, the Murtfeldt GROUP's expert for fibre-reinforced composites, various components have been integrated into the nu:view to combine highly specialised technology with the well-being of patients undergoing breast computed tomography. 

The combination was successful: The use of carbon-reinforced plastic in the contact surfaces, i.e. the imaging elements of nu:view, leads to impressive image resolutions. This allows potential tumours to be reliably detected, with the three-dimensional breast CT images providing a particularly precise diagnosis. On the other hand, the surfaces on which the patient's breast is scanned meet special ergonomic requirements.   


Crosslink played a key role in the development of these imaging components, in particular the breast shield and the breast sink. The design of these carbon components ensures maximum comfort during the examination, while the material, which has a thin partial lead coating, minimises radiation exposure. In addition, no compression of the breast tissue is required.  


This world first is based on spiral CT and photon counting technology. Unlike conventional scintillation, nu:view uses direct conversion detectors made of cadmium telluride (CdTe) to convert each X-ray photon directly into an electrical pulse. With nu:view, it is possible for the first time to visualise all parts of the female breast in true 3D with just one image. Seamless RIS/PACS integration ensures an optimised workflow. 


This is a precision manufacturing process: Crosslink developed the table top together with AB-CT and manufactures it for all breast CTs.  

nu:view in the field test


Radiologist Dr Karsten Ridder, head of the mammography screening programme at MVZ Prof. Dr Uhlenbrock & Partner in Dortmund, has already tested nu:view as a pain-free alternative to conventional mammography for breast cancer screening. The doctor's professional opinion is that the system is "absolutely high-tech" and is impressive for its completely compression-free, low-radiation and fast scanning process (around seven to twelve seconds). Another advantage is the open design, which reduces claustrophobia. 


At least 95% of patients are completely convinced after their first examination in the nu:view. "We have patients from Hamburg, Frankfurt and Düsseldorf. We also get visitors from Belgium and the Netherlands, especially from colleagues who want to know more," says Ridder.  

The research behind nu:view 



This new technology is based on the work of medical physicist Prof Dr Dr Willi Kalender, who has already played a key role in the development of spiral CT. In 2008, the professor began developing the compression-free CT scanner with PhD students from the Institute of Medical Physics at the University of Erlangen.  


The first prototype of the breast CT was built in 2014. After successfully passing the approval process, his son Benjamin Kalender took over the marketing of the new product in 2018, taking the breast CT from research to industry. There are currently seven units in use worldwide, four in hospitals and three in private practices. Five more machines have been sold and are in production. 


 

 

The future with nu:view 


The current weakness of this cancer screening method is the cost to the patient. In Dortmund, these amount to around 350 euros and are not yet covered by statutory health insurance. As a rule, the service is only covered by private health insurance companies. AB-CT is working on getting the new technology listed for statutory health insurance companies as well. The necessary study has already been commissioned by AB-CT. 

We would like to thank AB-CT for their confidence in us as a strong partner for the future of medical technology and we are honoured to be part of this important project.